Companies & Industry »Company News»Company News Details
Company News Details

BSE   20 Feb 18 | 12:00 AM

574.10 -9.75 (-1.67%)
Mkt Price (Rs)   Chg Rs (Chg %)
Code: 524804
Face Value: N.A.

NSE   20 Feb 18 | 12:00 AM

574.80 -8.15 (-1.4%)
Mkt Price (Rs)   Chg Rs (Chg %)
Code: AUROPHARMA
Performance
1 Week : Rs 601.85 (-4.61%)
1 Month : Rs 643.35 (-10.76%)
1 Year : Rs 685.90 (-16.30%)
change companytradenow
Back

Aurobindo Pharma gains on tentative nod for HIV drug

SI Reporter / Mumbai 22 Sep 16 | 12:53 PM

Aurobindo Pharma has moved higher by 4.4% to Rs 842 on the BSE after the company announced that it has received tentative approval for Dolutegravir 50mg from US Food & Drug Administration (USFDA). The drug is used for the treatment of HIV.

Dolutegravir 50mg is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.

Widgets Magazine

“The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Tivicay®, of ViiV Healthcare," Aurobindo Pharma said in a press release.

ViiV Healthcare and Aurobindo Pharma signed a licensing agreement in 2014 that allows Aurobindo Pharma to supply Dolutegravir 50mg in 92 licensed countries, following completion of required local regulatory approval processes, it added.

At 12:49 pm, the stock up 4% at Rs 839 on the BSE, as compared to 0.73% rise in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 4.2 million shares changed hands on the BSE and NSE so far.

Widgets Magazine

Sensex

Company Price Gain (%)
Coal India310.251.84
O N G C187.001.11
Bharti Airtel417.650.85
St Bk of India269.650.75
TCS2,945.050.70

Messages

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine